Discontinuation of Zandelisib Development Outside of Japan Following Recent FDA Meeting announced December 13, 2022
FDA accepts BLA of Denileukin Diftitox for the Treatment of Patients with Persistent or Recurrent Cutaneous T-Cell Lymphoma December 5, 2022
FDA Granted Regenerative Medicine Advanced Therapy (RMAT) and Fast Track Designations to CB-010 December 5, 2022
U.S. FDA Accepts for Priority Review the BLA for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of R/R Large B-Cell Lymphoma November 30, 2022
Topline Data from the Ph 2 MIRAGE Study of Zandelisib in Patients with Indolent B-cell NHL in Japan announced November 23, 2022
IGM Biosciences and ADC Therapeutics to Evaluate Imvotamab (IGM-2323) + ZYNLONTA in R/R B-cell NHL Patients November 16, 2022
BLAs for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of R/R LBCL and DLBCL submitted November 2, 2022
First Allogeneic CAR T Ph 2 ALPHA2 Trial of ALLO-501A in R/R LBCL Patients initiated October 12, 2022
First Patient Treated in Ph 1/2 Clinical Trial of MB-106 in B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia October 12, 2022
New Long-Term Data from L-MIND Shows Durable Response to Monjuvi® (tafasitamab-cxix) for R/R DLBCL Patients October 5, 2022
Positive CHMP Opinion for BRUKINSA® (zanubrutinib) for the Treatment of Adults with MZL September 28, 2022
Yescarta® Gets Positive CHMP Opinion For Use In 2L DLBCL And High-Grade B-Cell Lymphoma September 28, 2022
FDA approves Kymriah® CAR-T cell therapy for adult patients with R/R follicular lymphoma June 13, 2022
